Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
J Cell Physiol. 2020 Sep;235(9):5903-5924. doi: 10.1002/jcp.29593. Epub 2020 Feb 18.
Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small-molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases.
许多细胞因子是癌症和自身免疫性疾病的关键驱动因素。这些蛋白质与受体结合，并通过 Janus 激酶 (JAK) 和信号转导和转录激活因子 (STAT) 途径传递信号。JAK-STAT 途径中的遗传变异与癌症、自身免疫和炎症性疾病的风险增加有关。针对 JAK 和 STAT 的治疗可能是治疗这些疾病的安全有效的策略。托法替尼是第一种 JAK 抑制剂，已被批准用于治疗类风湿关节炎。此外，许多其他 JAK 抑制剂已被证明或正在各种临床试验阶段用于治疗各种疾病。目前，小分子 JAK 抑制剂被认为是治疗癌症和免疫介导性疾病的一类新型药物。
